By: Ariela Katz
VAL-083, a novel alkylating agent that has demonstrated potency against brain tumor cells and can overcome resistance associated with methylguanine methyltransferase (MGMT), is being investigated in patients with glioblastoma multiforme or gliosarcoma who had progressive disease during or after treatment with bevacizumab.
By: Richard Wong, MD
The incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.
By: Lisa Miller
Adjuvant therapy with tyrosine kinase inhibitors for patients with high-risk renal cell carcinoma (RCC) who have undergone a nephrectomy may be supported by level IIa evidence from the National Comprehensive Cancer Network guidelines.
By: Gina Battaglia, PhD
Immunotherapy has shown promise for treatment of glioblastoma multiforme (GBM), the most common primary brain tumor in adults with historically poor prognosis, but experts agree that combination regimens have the greatest potential to achieve durable response.
By: Christin Melton, ELS
The advent of new agents and new classes of agents for treating relapsed or refractory multiple myeloma, a notably complex disease state, has stimulated efforts to identify the optimal way to sequence or combine these therapies.
By: Maurie Markman, MD
Oncologists are well aware that by the time a new antineoplastic drug or regimen first enters the pages of a traditional reference textbook, the data supporting its use, including doses, schedules, and clinical indications, may already be considerably out-of-date.